Most Recent Articles by Linda Peckel
Nonadherence to treatment regimens presents a barrier to optimal outcomes in RA and lupus.
Many variations of therapy for rheumatoid arthritis are now possible, and determining the optimal strategy for each patient is crucial to the success of treatment.
Rapid expansion of effective therapies for psoriatic arthritis has driven new, ambitious treatment targets of minimal disease activity and disease remission.
Fibromyalgia has remained a clinically nebulous entity, and one that is very difficult to manage effectively.
Thoracic manifestations are common in connective tissue disease, also called collagen vascular disease.
More Articles by Linda Peckel
Rheumatology Advisor Articles
- Topical vs Oral NSAIDs for Rheumatoid Arthritis: Examining Cardiovascular Risks
- Update: 2017 Treat-to-Target Recommendations for Spondyloarthritis
- Risk for COPD, Asthma Examined in Women With Rheumatoid Arthritis
- Host Genetics May Affect Intestinal Microbiota Composition in Reactive Arthritis
- Introduction of bDMARDs Linked to Reduced Incidence of Total Knee Replacement
- Alogliptin May Be Associated With Lower Fracture Risk Compared With Linagliptin, Saxagliptin
- Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes
- Managing Treatment Nonadherence in Rheumatic Diseases
- Routine Vitamin D, Calcium Supplementation Not Associated With Fracture Reduction in Older Adults
- Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis
- Assessment of Nitrated Nucleosome Levels and Neuropsychiatric Events in Systemic Lupus Erythematosus
- Clinicians Who Share Email Addresses With Patients Have Higher Satisfaction Scores
- Biosimilar LBEC0101 Equivalent to ETN-RP for RA Unresponsive to Methotrexate
- Adalimumab Demonstrated Superior Efficacy Over Standard of Care in Refractory Uveitis
- Clinician Counseling for Exercise Increased Among Adults With Arthritis Between 2002 and 2014